A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant
Status:
Completed
Trial end date:
2020-12-14
Target enrollment:
Participant gender:
Summary
The primary objective of this multiple-dose, adaptive design study is to evaluate the effect
of hepatic impairment on the pharmacokinetics (PK) of relacorilant relative to healthy
matched control male and female subjects (Part 1).